AzurRx BioPharma (NASDAQ: AZRX) is one of 104 publicly-traded companies in the “Pharmaceuticals” industry, but how does it compare to its competitors? We will compare AzurRx BioPharma to related businesses based on the strength of its risk, dividends, institutional ownership, valuation, earnings, analyst recommendations and profitability.
This table compares AzurRx BioPharma and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|AzurRx BioPharma Competitors||-2,431.57%||-57.20%||-7.36%|
8.2% of AzurRx BioPharma shares are owned by institutional investors. Comparatively, 43.2% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 9.1% of AzurRx BioPharma shares are owned by company insiders. Comparatively, 12.0% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
This is a summary of recent ratings and recommmendations for AzurRx BioPharma and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|AzurRx BioPharma Competitors||985||3951||6937||189||2.52|
AzurRx BioPharma presently has a consensus price target of $8.00, suggesting a potential upside of 158.06%. As a group, “Pharmaceuticals” companies have a potential upside of 19.89%. Given AzurRx BioPharma’s stronger consensus rating and higher probable upside, equities analysts plainly believe AzurRx BioPharma is more favorable than its competitors.
Valuation and Earnings
This table compares AzurRx BioPharma and its competitors top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|AzurRx BioPharma||N/A||-$14.59 million||-2.15|
|AzurRx BioPharma Competitors||$8.54 billion||$1.11 billion||160.59|
AzurRx BioPharma’s competitors have higher revenue and earnings than AzurRx BioPharma. AzurRx BioPharma is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
AzurRx BioPharma competitors beat AzurRx BioPharma on 8 of the 12 factors compared.
About AzurRx BioPharma
AzurRx BioPharma, Inc. is a clinical development-stage biopharmaceutical company. The Company is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal (GI) disorders. The Company’s product pipeline consists of two therapeutic proteins, such as MS1819 and AZX1101. MS1819 is an acid-resistant secreted lipase produced by Yarrowia lipolytica, known as LIP2, that the Company is developing through recombinant deoxyribonucleic acid (DNA) technology for the treatment of exocrine pancreatic insufficiency (EPI), associated with chronic pancreatitis (CP) and cystic fibrosis (CF). AZX1101 is a recombinant-lactamase combination of bacterial origin under development for the prevention of hospital-acquired infections by resistant bacterial strains induced by parenteral administration of b-lactam antibiotics (known as nosocomial infections), as well as the prevention of antibiotic-associated diarrhea (AAD).
Receive News & Ratings for AzurRx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AzurRx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.